Outgoing Ironwood CEO Mark Mallon
February 9, 2021 07:09 AM ESTUpdated 08:02 AM
People

Mark Mal­lon wraps a short stint as CEO of Iron­wood, jump­ing out to pur­sue 'mul­ti­ple pas­sion­s' in the wake of set­backs

John Carroll

Editor & Founder

Mark Mal­lon built his ca­reer over a 24-year stretch at As­traZeneca. But he man­aged less than 2 years as CEO of Iron­wood.

Iron­wood an­nounced Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis pays $1B up­front for PTC's Phase 2 Hunt­ing­ton's drug

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

Merus drug shows ‘un­ex­pect­ed im­prove­ment’ in sec­ond-line head and neck can­cer study

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Novo­cure says elec­tric field ther­a­py ex­tends life for pan­cre­at­ic can­cer pa­tients by two months

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times